A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A
收藏DataCite Commons2024-12-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006552/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To assess efficacy and safety, including immunogenicity of BAX 855 administered as
prophylaxis and as on-demand therapy in adult and adolescent (12-65 years) previously treated
patients (PTPs) with severe hemophilia A To determine the pharmacokinetic (PK) parameters of
BAX 855.
提供机构：
Vivli
创建时间：
2021-01-19
